# Regeneron

leveraging human genetic databases to rapidly discover and commercialize novel targeted antibodies.

Source: https://en.bioecon.ru/companies/regeneron/
Updated: 2026-06-24

- Country: United States
- Ticker: REGN

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | $14.34 billion (2025-12-31) | https://investor.regeneron.com/static-files/6f7d5806-3db5-410d-9bef-36e44c57bfce |
| Headcount | 15,410 employees (2025-12-31) | https://www.regeneron.com/about/our-company |
| Production site | Rensselaer, New York and Limerick, Ireland (2025-12-31) | https://investor.regeneron.com/pdf/2025AR, https://investor.regeneron.com/static-files/6f7d5806-3db5-410d-9bef-36e44c57bfce |
| Capacity | Approximately 100,000 liters (Rensselaer) and 120,000 liters (Limerick) of cell culture capacity (2025-12-31) | https://investor.regeneron.com/pdf/2025AR, https://investor.regeneron.com/static-files/6f7d5806-3db5-410d-9bef-36e44c57bfce |
| Certification | UK GMP Compliance Certificate for Rensselaer facility (2017-03-20) [medium confidence] | https://cms.mhra.gov.uk/index.php/mhra/gmp/uk-gmp-25041-insp-gmp-25041794754-0004h |
| Regulatory approval | Facilities approved by the FDA and other regulatory agencies to manufacture bulk drug materials and products (2025-12-31) | https://investor.regeneron.com/pdf/2025AR, https://investor.regeneron.com/static-files/6f7d5806-3db5-410d-9bef-36e44c57bfce |
| Funding | Sanofi is generally responsible for funding 80% to 100% of agreed-upon development expenses in their antibody collaboration (2025-12-31) | https://investor.regeneron.com/pdf/2025AR, https://investor.regeneron.com/static-files/6f7d5806-3db5-410d-9bef-36e44c57bfce |

Independent sources: cms.mhra.gov.uk

## Technologies

- [Biopharmaceuticals & biomedicines](https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/)
- [Bispecific & multispecific antibodies](https://en.bioecon.ru/technology/bispecific-antibodies/)